drugset / Trial / NCT00764751

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

NCT00764751

Phase 2 Completed 51 enrolled LEO Pharma
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will compare the efficacy and safety of once daily treatment of LEO 19123 cream versus Dovonex® cream (applied twice daily) and versus LEO 19123 cream vehicle alone (applied twice daily) in subjects with psoriasis vulgaris. Subject will be treated for 4 weeks. All subjects will apply LEO 19123 cream to psoriasis lesions on the left or right side of the body and either Dovonex® cream or cream vehicle to lesions on the other side.

Timeline

Start
2008-09
Primary completion
2008-12
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcipotriol Small molecule
Subject LEO80122 Unknown

Indications